The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Hodgkin lymphoma highlights from ASH 2023: nivo-AVD versus BV-AVD in patients with HL
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, shares his highlights in Hodgkin lymphoma (HL) from the 2023 ASH Annual Meeting, commenting on the interesting benefit observed with the use of nivolumab-AVD (nivo-AVD) versus brentuximab vedotin-AVD (BV-AVD) in both elderly and younger patients with HL. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
ADC Therapeutics: Research Funding; Pfizer: Research Funding; AstraZeneca: Research Funding; Affimed: Research Funding; Takeda: Research Funding; SeaGen: Research Funding; BMS: Research Funding; Regeneron Pharmaceuticals, Inc.: Research Funding.
